Oded Orgil is listed as a director on 11 SEC Form D filings by 1 issuer between Oct 2023 and Aug 2026: NurExone Biologic Inc. (Technion City, Haifa, Israel (as filed: L3) — biotechnology — 2023–2026; $1.63M reported sold to 6 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Eran Ovadya (11 shared filings), Lior Shaltiel (11 shared filings), Yoram Drucker (11 shared filings), James Richardson (10 shared filings), Gadi Riesenfeld (4 shared filings) and 2 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Oded. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 court cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 11 public filings for Oded Orgil and found 7 differences: Form D filed 38 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.